In the multidisciplinary tumour board first-line immuno-chemotherapy was initially considered as an appropriate treatment option, because specific exon-20 targeted therapies were not yet available at the time of diagnosis and single agent immunotherapy is considered as less effective in EGFR-mutated lung carcinomas even with high PDL1 expression. This evidence concerns the gene EGFR and neoplasm.